IFRX — InflaRx N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1708688 ·
Last close
$1.70
Market Cap
$250.40M
52W High
$2.95
52W Low
$1.54
ADV30
1,200,237
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -7,208,150 | -5,592,649 | 48,889,811 | 14,993,792 | 11,999,608 |
| Dec 2025 | -33,931 | -4,892,342 | -12,856,841 | -10,642,393 | 55,216,297 | 16,022,171 | 13,659,516 |
| Sep 2025 | 23,830 | 23,497 | -9,477,005 | -12,261,089 | 65,157,050 | 6,448,116 | 19,790,235 |
| Jun 2025 | 39,432 | -2,360,151 | -12,825,155 | -14,416,271 | 73,442,172 | 13,003,451 | 16,397,807 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-35,314,327
Investing CF
$3,233,049
Financing CF
$33,316,647
CapEx
$-115,694
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-377,826,001
Inventory
$0
Receivables
$1,428,428
ST Investments
$30,435,088
EBIT TTM
$-45,489,424
Pretax Income TTM
$-45,528,663
Interest Exp TTM
$39,239
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$29,331
EBITDA
$-42,427,844
Free Cash Flow
$-15,887,300
Enterprise Value
$83,920,200
Total Cash
$39,800,688
Total Debt
$823,028
Shares Out
147,292,859
Trailing EPS
$-0.72
Book Value
$0.58
ROE
-79.9%
ROA
-39.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 29,331 | -48,256,974 | -45,633,780 | 55,216,297 | 13,659,516 | — | -35,314,328 |
| Dec 2024 | 165,789 | -52,905,579 | -46,064,402 | 76,018,457 | 14,602,418 | — | -48,556,690 |
| Dec 2023 | 63,089 | -44,594,856 | -42,667,529 | 120,208,551 | 17,626,821 | — | -37,812,966 |
| Dec 2022 | 0 | -32,237,867 | -29,484,611 | 102,399,660 | 14,050,220 | — | -33,742,817 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.43
Max Pain — expiry 2026-08-21
max pain strike: $2.00 · spot: $1.70 · call oi: 1,542 · put oi: 76Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TTRX | Turn Therapeutics Inc. | $249.03M | $8.36 | — |
| VRXA | Veraxa Biotech Holding AG | $248.88M | $1.76 | — |
| ADAG | Adagene Inc. | $247.77M | $3.75 | — |
| PRQR | ProQR Therapeutics N.V. | $242.73M | $1.72 | — |
| CYDY | CytoDyn Inc. | $260.25M | $0.19 | — |
News headlines (Yahoo Finance, 1h cache)
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
2026-07-30 11:30 · Yahoo
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
2026-06-30 11:30 · Yahoo
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
2026-06-26 09:16 · Yahoo
What Do Analysts Say About InflaRx N.V. (IFRX)?
2026-06-10 18:22 · Yahoo
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now
2026-05-31 10:55 · Yahoo
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
2026-05-08 15:53 · Yahoo
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
2026-05-08 12:15 · Yahoo
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq
2026-05-07 17:28 · Yahoo
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
2026-05-06 12:30 · Yahoo
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
2026-05-06 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.